



**HAL**  
open science

## **Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial**

Abdel-Rahmène Azzouzi, Sébastien Vincendeau, Eric Barret, Antony Cicco, François Kleinclauss, Henk G. van Der Poel, Christian G. Stief, Jens Rassweiler, Georg Salomon, Eduardo Solsona, et al.

### ► **To cite this version:**

Abdel-Rahmène Azzouzi, Sébastien Vincendeau, Eric Barret, Antony Cicco, François Kleinclauss, et al.. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. *Lancet Oncology*, 2017, 18 (2), pp.181-191. 10.1016/S1470-2045(16)30661-1 . hal-01484971

**HAL Id: hal-01484971**

**<https://univ-rennes.hal.science/hal-01484971>**

Submitted on 21 Jun 2018

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **TITLE:** Padeliporfin Vascular-targeted Photodynamic Therapy Versus Active Surveillance:  
2 A Randomised Clinical Trial in Men with Low-risk Prostate Cancer

3 **RUNNING TITLE:** Photodynamic Therapy for Low-risk Prostate Cancer

4 **AUTHORS AND AFFILIATIONS:**

5 Abdel-Rahmène Azzouzi, M.D.<sup>1</sup>, Sébastien Vincendeau, M.D.<sup>2</sup>, Eric Barret, M.D.<sup>3</sup>, Antony  
6 Cicco, M.D.<sup>4</sup>, François Kleinclauss, M.D.<sup>5</sup>, Henk G. van der Poel, M.D.<sup>6</sup>, Christian G. Stief,  
7 M.D.<sup>7</sup>, Jens Rassweiler, M.D.<sup>8</sup>, Georg Salomon, M.D.<sup>9</sup>, Eduardo Solsona, M.D.<sup>10</sup>, Antonio  
8 Alcaraz, M.D.<sup>11</sup>, Teuvo T. Tammela, M.D.<sup>12</sup>, Derek J. Rosario, M.D.<sup>13</sup>, Francisco Gomez-  
9 Veiga, M.D.<sup>14</sup>, Göran Ahlgren, M.D.<sup>15</sup>, Fawzi Benzaghrou, M.D.<sup>16</sup>, Bertrand Gaillac, M.D.<sup>16</sup>,  
10 Billy Amzal, Ph.D.<sup>17</sup>, Frans M.J. Debruyne, M.D.<sup>18</sup>, Gaëlle Fromont, M.D.<sup>19</sup>, Christian  
11 Gratzke, M.D.<sup>7</sup>, Mark Emberton, FMedSci<sup>20</sup> on behalf of the PCM301 Study Group

12 <sup>1</sup> Department of Urology, Angers University Hospital, Angers, France

13 <sup>2</sup> Department of Urology, CIC-INSERM 1414, Rennes University Hospital, Rennes, France

14 <sup>3</sup> Department of Urology, Institut Montsouris, Université Paris Descartes, Paris, France

15 <sup>4</sup> Department of Urology, Centre Catalan Urologie Andrologie, Cabestany, France

16 <sup>5</sup> Department of Urology, Besançon University Hospital, Besançon, France

17 <sup>6</sup> Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital,  
18 Amsterdam, The Netherlands

19 <sup>7</sup> Department of Urology, LMU-Klinikum der Universität München, Munich, Germany

20 <sup>8</sup> Department of Urology, SLK Kliniken, Heilbronn, Germany

21 <sup>9</sup> Martini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf,  
22 Hamburg, Germany

23 <sup>10</sup> Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain

24 <sup>11</sup> Department of Urology, Hospital Clinic, Barcelona, Spain

25 <sup>12</sup> Department of Urology, Tampere University Hospital and School of Medicine, Tampere,  
26 Finland

27 <sup>13</sup> Academic Department of Urology, University of Sheffield, Royal Hallamshire Hospital,  
28 Sheffield, UK

29 <sup>14</sup> Department of Urology, Salamanca University Hospital GITUR-IBSAL, Salamanca, Spain  
30 and Department of Complex University Hospital, La Coruna, Spain

31 <sup>15</sup> Department of Urology, Skåne University Hospital, Malmö, Sweden

32 <sup>16</sup> Medical Department, STEBA Biotech, Paris, France

33 <sup>17</sup> LA-SER Analytica, London, UK

34 <sup>18</sup> Andros Men's Health Institute, Arnhem, The Netherlands

35 <sup>19</sup> Department of Pathology, Tours University Hospital, Tours, France

36 <sup>20</sup> Division of Surgery and Interventional Science, University College London, London, UK

37 **CORRESPONDING AUTHOR:** Prof. Mark Emberton

38 **Address:** UCL Faculty of Medical Sciences, 1A Maple House, 149 Tottenham Court Road,  
39 London W1T 7NF, UK

40 **Phone:** +44 (0)203 108 2105

41 **Email:** m.emberton@ucl.ac.uk

## 42 **SUMMARY**

### 43 *Background*

44 Vascular-targeted photodynamic therapy (VTP), a novel tissue-preserving treatment for low-  
45 risk prostate cancer (PC), has shown favorable safety and efficacy results in single-arm Phase  
46 I and II studies. This report presents results of a randomised, controlled, parallel-group  
47 clinical trial of padeliporfin VTP versus the standard of care, active surveillance (AS).

### 48 *Methods*

49 Men with low-risk, localised PC (no Gleason patterns 4 or 5) and no previous treatment were  
50 recruited from March 8, 2011 to April 30, 2013 at 47 European university centres and  
51 community hospitals. They were randomised (stratification by centre using balanced blocks)  
52 to VTP or AS. VTP consisted of 4 mg/kg padeliporfin administered intravenously over ten  
53 minutes via optical fibres inserted into the prostate to cover the desired treatment zone and  
54 subsequent activation by laser light for 22 minutes and 15 seconds. Both groups were  
55 followed-up for 24 months in accordance with best AS practice at the time of study design,  
56 i.e., biopsy at 12-month intervals and prostate-specific antigen measurement and digital rectal  
57 exam at 3-month intervals. The prespecified co-primary efficacy endpoints were histological  
58 progression of cancer and absence of any histology result definitively positive for cancer at  
59 Month 24. Treatment was open-label, but primary efficacy outcomes were evaluated in a  
60 blinded manner.

### 61 *Findings*

62 Of the 206 subjects randomised to VTP, 196 received treatment. At completion of the trial,  
63 all 413 randomised subjects (intention-to-treat population) were analysed for efficacy. VTP  
64 doubled time to progression (from 14.1 [95% CI: 12.9 to 23.8] months to 28.3 [95% CI: 26.0

65 to 30.6] months;  $p < 0.0001$ ) and reduced the progression rate to approximately one-third that  
66 of AS (adjusted hazard ratio = 0.34; 95% CI: 0.24, 0.46;  $p < 0.0001$ ). VTP increased the  
67 probability of a negative prostate biopsy at 24 months post-treatment from 13.5% (28 of 207  
68 subjects) to 49.0% (101 of 206 subjects) (adjusted risk ratio: 3.67; 95% CI: 2.53, 5.33);  
69  $p < 0.0001$ ).

70 VTP was well tolerated. Genitourinary function showed transient deterioration in the VTP  
71 group, but no significant effects were seen at Month 24. The most common AEs in the VTP  
72 group were urinary tract infections (21 subjects) and AEs in the renal and urinary disorders  
73 (133 subjects) and reproductive system and breast disorders system organ classes (121  
74 subjects). The most common serious side effect was retention of urine. Typically this event  
75 occurred on the first attempt to withdraw the urinary catheter (day-1 post-op). This was  
76 managed with immediate re-catheterization. The timing of a second attempt at removal of the  
77 urinary catheter was left to the discretion of the local investigator. This event occurred in 15  
78 subjects, was severe in 3 subjects, and resolved within two months in all cases.

### 79 ***Interpretation***

80 Padeliporfin VTP is a safe effective treatment for low-risk, localised PC that reduces the rate  
81 of histological progression compared to AS. It may allow more men to consider a tissue-  
82 preserving approach and defer or avoid radical therapy.

### 83 ***Funding***

84 STEBA Biotech S.A.

### 85 ***Registration***

86 ClinicalTrials.gov NCT01310894

87

88 **RESEARCH IN CONTEXT**

89 *Evidence before this study*

90 The idea of modifying our therapeutic target from the host organ to the tumour plus a margin  
91 has been the mainstay of surgical oncology during the latter half of the 20<sup>th</sup> century. The  
92 principle is probably best exemplified in breast cancer, for which the previous standard of  
93 care, the Halsted radical mastectomy, has, with time and accumulating evidence, largely been  
94 replaced by breast preservation achieved by local excision with or without radiotherapy. We  
95 have seen the same process in renal cancer. Radical nephrectomy is currently performed only  
96 when partial nephrectomy and nephron preservation is neither practical nor possible. Ten  
97 years ago it was performed in all patients. The principles behind this transition are  
98 equivalence in terms of cancer-related outcomes but better function, greater patient  
99 acceptability, quicker recovery, and enhanced survivorship. Prostate cancer (PC) is the only  
100 solid organ cancer left for which this principle is not generally applied. Over the last decade  
101 several proof-of-concept studies of focal therapy for PC have been published, but they have  
102 typically been single-centre, small, and of relatively low quality. Having said this, these  
103 studies demonstrated the feasibility of more targeted treatment for PC and more importantly  
104 suggested high levels of patient acceptability because of excellent functional outcomes. More  
105 recently we have seen registered prospective development studies and formal Phase I and  
106 Phase II studies that demonstrate both safety and early (short-term) oncological efficacy.  
107 These studies have been summarised in Valerio's systematic review.

108 *Added value of this study*

109 Valerio's systematic review identified the need for comparative studies. To our knowledge,  
110 ours is the first such study. Because vascular-targeted photodynamic therapy (VTP) is an  
111 intervention involving both a drug (in this case, padeliporfin) and a device (laser light  
112 introduced into the prostate), it was subject to regulatory approval as a drug through the  
113 European Medicines Agency (EMA). A pivotal comparative study was thus necessary but  
114 was challenging to design in a manner that would be acceptable to both patients and  
115 clinicians and in which the same primary outcome could be assessed for both VTP and the  
116 comparator. We had three options for the comparator: surgery, radiotherapy, or active  
117 surveillance (AS). The first two were problematic in arriving at a primary outcome that could  
118 be applied to both the experimental arm and the control. Surgery (radical prostatectomy)  
119 would not be suitable for a biopsy-based outcome because there would be no prostate to  
120 biopsy. Radiotherapy, on the other hand, would be amenable to a protocol-required biopsy,  
121 but the histological outcome would be confounded by the necessary neoadjuvant and  
122 adjuvant androgen suppression that comprises the standard of care. Therefore, AS was the  
123 only comparator that could reasonably be employed over the intended time frame of the  
124 study. The task for the EMA and the PCM301 Study Group was to determine the upper and  
125 lower risk thresholds of this low-risk group that would define the upper and lower bounds of  
126 the study entry criteria. These criteria had the effect of excluding, within the limits of  
127 precision of the diagnostic methods available to us at the time, men that were at very low risk  
128 and therefore unlikely to progress and men that were at higher risk and therefore unlikely to  
129 be offered or indeed consent to AS.

130 These thresholds of low risk were in keeping with standard practice at the time of study  
131 design. Recent publications from Scandinavia and Canada on mature AS populations have  
132 subsequently shown that men towards the upper threshold of low-risk PC do fare worse in  
133 progression than men with very-low-risk disease. Modern diagnostic methods, including

134 magnetic resonance imaging, allow us to identify these risk groups with considerably greater  
135 precision today than was possible at the time when the study was being considered by the  
136 EMA. Our results show that men with localised, low-risk PC can be treated in a way that not  
137 only preserves their genitourinary function but also results in a lower progression rate, greater  
138 chance of being declared disease-free, and reduction in need for whole-gland radical therapy  
139 in the form of surgery or radiotherapy.

#### 140 *Implications of all the available evidence*

141 When this study was designed, our risk stratification methods at diagnosis were poor. The  
142 correction that was applied to mitigate the consequences of this imprecision was to offer  
143 radical therapy to nearly all men, irrespective of attributed risk. Today we attribute risk with  
144 greater precision using risk calculators, biomarkers, and imaging. Our study adds  
145 considerable weight to the argument that we need to move away from a one-size-fits-all  
146 approach to treatment and gradually replace it with a more risk-stratified approach to care.  
147 We have AS for men at very low risk. We have radical therapy and multimodality treatments  
148 for men at high risk for whom the consequences of treatment are matched by benefit.  
149 Between these two extremes, we now have VTP, an intervention that preserves prostate tissue  
150 when it is both possible and practical to do so. Given the precision of today's risk  
151 stratification, future research will need to explore both the patient preferences and the upper  
152 threshold of risk (as defined by tumour grade, volume, location, multiplicity) that should  
153 determine where the transition point exists where tissue preservation is likely to confer  
154 diminishing returns and should be supplanted by whole-gland radical therapy.

155

## 156 **INTRODUCTION**



157 Active surveillance (AS), a policy of delayed selective intervention, is an appropriate  
158 therapeutic option for low-risk prostate cancer (PC) that helps to mitigate the consequences  
159 of overtreatment.<sup>1</sup> Most studies—though admittedly single-centre and noncomparative—have  
160 demonstrated favorable outcomes, but AS has been associated with fairly high intervention  
161 rates especially in cohorts with less stringent eligibility criteria.<sup>2</sup> Intervention, or crossover to  
162 radical treatment (surgery or radiotherapy) or systemic therapy (androgen suppression), tends  
163 to be driven by—in descending order of frequency—pathological upgrading on repeat biopsy,  
164 biochemical progression, and patient choice.<sup>3</sup>

165 Focal therapy and AS are both tissue-preserving strategies. They share the goal of preserving  
166 prostate tissue and consequently function by delaying or avoiding radical whole-gland  
167 treatment in men in whom it is safe to do so.<sup>4</sup> However, focal therapy differs from AS in that  
168 it treats disease—by the process of selective tissue ablation—above a certain risk threshold  
169 and monitors disease below that threshold, as the latter is deemed to be clinically  
170 insignificant. A risk-stratified clinical pathway that offers men focal therapy in a manner  
171 complementary to AS might result in two potential benefits: a reduction in the probability of  
172 failure or crossover to radical therapy and an increase in the proportion of men eligible and  
173 willing to undergo a tissue-preserving treatment.

174 Neither focal therapy nor AS has previously been assessed in a prospective, comparative  
175 efficacy study. Both have been assessed only in single-centre series,<sup>2,5,6</sup> in which the  
176 outcomes were dependent on the population studied, the diagnostic precision at baseline, the  
177 intensity and manner of the reclassification tests, and the study duration. These limitations  
178 challenge informed decision-making by the patient because the attributes that are most likely  
179 to influence treatment selection are the failure rates and toxicity profiles of the two  
180 approaches and the likelihood of avoiding radical therapy. We present the results of what is to  
181 our knowledge both the first prospective comparative evaluation of the efficacy and safety of

182 focal therapy and the first evaluation of AS in a comparative setting—rather surprisingly  
183 given that it is a recommended standard of care. The selective ablation in our focal therapy  
184 arm was achieved using vascular-targeted photodynamic therapy (VTP) with padeliporfin, an  
185 agent that achieves its tissue effects nonthermally and had previously been evaluated in both  
186 preclinical and clinical settings.<sup>7,8</sup>

## 187 **METHODS**

### 188 *Study design and participants*

189 Study CLIN1001 PCM301 was a randomised, controlled, parallel-group clinical trial of  
190 padeliporfin VTP versus AS for treatment of low-risk, localised PC. Men aged  $\geq 18$  years  
191 with low-risk, localised PC diagnosed by transrectal ultrasound (TRUS)-guided biopsy and  
192 no previous treatment were enrolled, provided they were eligible to be exposed to a  
193 photosensitising agent and had no contraindications to undergoing magnetic resonance  
194 imaging (MRI). Participants were required to have low-risk PC but not very–low-risk PC.  
195 Men were eligible if one core of cancer that was free of Gleason patterns 4 or 5 was present  
196 provided that the cancer core length was between 3 and 5 mm. In other words, if only one  
197 core was positive, only Gleason pattern 3 was permitted but in order to qualify the cancer  
198 core length had to be greater than or equal to 3mm and less than or equal to 5mm. Men with 2  
199 or 3 cores positive were also permitted, but cancer core length could not exceed 5 mm.  
200 Clinical stage was limited to  $\leq T2a$  (pathological or radiological up to T2c disease permitted),  
201 prostate-specific antigen (PSA)  $\leq 10$  ng/mL, and prostate volume  $\geq 25$  and  $< 70$  cc). These  
202 criteria were based on a study of prediction determinants prediction in AS subsequently  
203 reported by Welty et al.<sup>9</sup> The performance status of the subjects was not a criterion for study  
204 inclusion. Instead, two overarching requirements had to be satisfied: men had to have a  
205 predicted life expectancy of 10 years or more and, in addition, had to be free of any medical

206 conditions that were deemed to be a contraindication to general anaesthesia. Men with a  
207 contraindication to MRI (e.g. cardiac pacemaker), factors excluding accurate reading of  
208 pelvic MRI (e.g. bilateral hip replacements), or any condition or history of illness or surgery  
209 that may have posed an additional risk to men undergoing VTP procedure were excluded.  
210 Criteria for subject removal from the study were occurrence of a serious adverse event (SAE)  
211 if recommended by the investigator, subject withdrawal, or a major protocol violation.

212

213 The study was conducted in compliance with Good Clinical Practice and according to a  
214 written protocol approved by each centre's ethics committee. All subjects provided written  
215 informed consent. The trial was completed in accordance with the protocol.

216

### 217 ***Randomisation and masking***

218 Investigators enrolled subjects and allocated them to the VTP and AS groups in a 1:1 ratio  
219 using a web-based randomisation system generated by the sponsor and stratified by centre  
220 using balanced blocks of varied size (2 or 4 subjects). Treatment was open-label (subjects  
221 and investigational site staff were not blinded to study treatment), but primary efficacy  
222 outcomes were evaluated in a blinded manner.

### 223 ***Procedures***

224 AS was conducted according to best practice at the time of study design.<sup>10,11</sup> It comprised a  
225 protocol-directed biopsy at 12-month intervals and 3-monthly PSA measurement coupled  
226 with a digital rectal exam.

227 The aim of VTP was to treat a complete prostate lobe. Subjects randomised to padeliporfin  
228 VTP underwent pretreatment multiparametric MRI, which was centrally reviewed with the

229 biopsy results by a committee composed of radiologists and urologists who made detailed  
230 recommendations on the number, length, and position of interstitial optical fibres using  
231 treatment guidance software.<sup>8,12</sup> The treatment-guidance software was used to generate a  
232 light-density index (LDI; a measure of the energy exposure per unit volume of target tissue)  
233 of >1, which had been associated with a high probability of a single-lobe ablation in earlier  
234 studies.<sup>8</sup> However, the urologist in charge of the treatment was allowed to adapt the treatment  
235 recommendations to the actual volume and shape of the prostate observed on the TRUS  
236 images at the time of the procedure. Once the fibres were accurately positioned in the  
237 prostate to cover the desired treatment zone, 4 mg/kg padeliporfin (Aptuit Glasgow Ltd,  
238 Glasgow, UK) was administered intravenously over ten minutes. The drug was activated in  
239 the treatment zone by laser light at 753 nm with a fixed power of 150 mW/cm over  
240 22 minutes and 15 seconds, corresponding to an energy dose of 200 J/cm.<sup>13</sup> Subjects with  
241 bilateral cancer received a second procedure for contralateral lobe treatment. Retreatment of  
242 lobes positive for PC at the Month 12 biopsy was permitted. The VTP procedure was carried  
243 out under a general anaesthetic during a 2-hour operating theatre allocation with a planned  
244 overnight stay. The urethral catheter was removed the morning after the procedure.

245 For subjects in both groups, PSA was measured and digital rectal examination performed  
246 every three months. TRUS-guided, 12-core biopsy (6 cores directed to each prostate lobe)  
247 was performed at Months 12 and 24. Thus, the sampling density (number of cores per unit  
248 volume of tissue) in the subjects who received VTP was greater than in those in the AS  
249 group, particularly for VTP-treated lobe(s) with reduced volume associated with post-  
250 treatment fibrosis. Biopsy samples were read centrally by an independent pathologist blinded  
251 to treatment assignment and local pathologist reading. An independent, blinded Outcomes  
252 Review Panel reviewed all PSA data and TRUS-guided biopsy reports to assess these results  
253 and determined the number and location of positive cores. In the case of discrepancy between

254 the local and central biopsy readings, the panel's pathologist adjudicated. Any additional  
255 radical PC treatments, metastases, evidence of T3 disease, and severe PC-related events were  
256 recorded at Months 12 and 24. Any man who underwent radical PC treatment without  
257 histological progression (because of patient or physician preference) continued in the study  
258 until the end (Month 24) and returned to standard care after that.

259 The International Prostate Symptom Score (IPSS) and International Index of Erectile  
260 Function – 15 Questions (IIEF-15) questionnaires were administered every three months  
261 through Month 12 and at Month 24 (and at seven days postprocedure for subjects who  
262 received padeliporfin VTP). Validity and sensitivity of these questionnaires to detect change  
263 in genitourinary function have been established.<sup>14,15</sup> The EuroQol-5D (EQ-5D) questionnaire  
264 was administered at Month 12 and Month 24 to assess quality of life. All adverse events  
265 (AEs) were recorded from the signing of the consent form through the end of the study  
266 (including any occurring after the initiation of additional PC treatment). At each study visit,  
267 the investigator questioned the subject about AEs and intercurrent illnesses since his last visit.  
268 The questions were general, and the presence or absence of specific AEs was not solicited  
269 from subjects. AE severity was graded according to the National Cancer Institute Common  
270 Terminology Criteria for Adverse Events version 4.03. The investigator assessed the  
271 relationship of each AE to the study drug (padeliporfin), device, and procedure. AEs were  
272 coded and categorised according to the Medical Dictionary for Regulatory Activities  
273 (version: 18.0). Haematology, coagulation, serum chemistry, and urinalysis were evaluated  
274 every three months. Troponin was measured before discharge and quantitative D-Dimer  
275 before anaesthesia, before discharge, and at 7 days post-treatment for subjects who received  
276 VTP. Vital signs, electrocardiogram, and physical examination were performed preprocedure  
277 and postprocedure for subjects who received padeliporfin VTP. An independent Data Safety  
278 Monitoring Board (composed of two urologists, a laser surgery expert, and a statistician)

279 reviewed safety data and SAE reports throughout the study and advised the sponsor on  
280 matters of subject safety.

### 281 ***Outcomes***

282 The prespecified co-primary efficacy endpoints were treatment failure (histological  
283 progression of cancer from low to moderate or higher risk over 24 months follow-up) and  
284 absence of definitive cancer (absence of any histology result definitively positive for cancer  
285 at Month 24). Moderate or higher risk was defined as the observation of one of the following  
286 events: more than three cores definitively positive for cancer when considering all  
287 histological results available during follow-up in the study, any Gleason primary or  
288 secondary pattern of 4 or more, at least one cancer core length >5 mm, PSA > 10 ng/mL in  
289 three consecutive measures, any T3 PC, metastasis, PC-related death. The prespecified  
290 secondary objective was to determine any differences between the two groups in the  
291 following outcomes: total cancer burden in the prostate; rate of additional PC radical therapy;  
292 rate of severe PC-related events (cancer extension to T3, metastasis, PC-related death); rate  
293 of AEs; rate of incontinence, erectile dysfunction, and urinary symptoms.

### 294 ***Statistical analysis***

295 The sample size was based on an expected rate of progression from low to moderate or higher  
296 risk of  $\geq 15\%$  over 2 years in the AS group and 5% in the VTP group. Using these  
297 assumptions, the sample size required was 400 subjects (200 subjects per group), and at least  
298 40 events (subjects with progression of cancer) needed to be observed for the final analysis to  
299 take place.

300 Statistical analyses were conducted using SAS version 9.3. All randomised subjects were  
301 analysed for efficacy according to assigned treatment in an intention-to-treat analysis.

302 Treatment failure (progression) was analysed by survival analysis. Times to progression were  
303 compared between the two treatment groups using the log-rank test and quantified using a  
304 Cox proportional-hazards regression model to derive hazard ratios at Month 24, and  
305 treatment group and age, number of positive cores, prostate volume, and disease status at  
306 baseline were used as covariates. Absence of definitive cancer (positive biopsy) was analysed  
307 as a dichotomous outcome. Proportions of subjects with observed success at Month 24 were  
308 compared by 2-sided Pearson's chi-square test, and odds and risk ratios were calculated.  
309 Time to initiation of radical therapy was estimated by the Kaplan-Meier method, and the log-  
310 rank test was used for comparison. The mean number of positive cores and maximum cancer  
311 core length at Months 12 and 24 were compared by Student *t* test. Other efficacy data were  
312 summarised descriptively.

313 All subjects randomised to VTP who received any padeliporfin or initiated any study  
314 treatment-related procedure and all subjects randomised to AS were analysed for safety by  
315 treatment received. IIEF-15, IPSS, and EQ-5D results were analysed by analysis of  
316 covariance. Other safety data, including, AEs, were summarised descriptively.

317 The trial is registered at ClinicalTrials.gov (NCT01310894).

### 318 ***Role of the funding source***

319 The study sponsor and funder, STEBA Biotech S.A., developed the protocol in consultation  
320 with the study investigators and the European Medicines Agency (EMA). STEBA performed  
321 data management and statistical analysis and provided medical writing support for this report.  
322 AAzzouzi and ME had full access to all data in the study. The final decision to submit this  
323 report for publication was made jointly by all the authors. The corresponding author (ME)  
324 had the final responsibility to submit for publication.

325 **RESULTS**

326 Subjects were recruited from March 8, 2011 to April 30, 2013 and followed for  
327 approximately 24 months at 47 university centres at community hospitals in ten European  
328 countries (Belgium, Finland, France, Germany, Italy, Netherlands, Spain, Sweden,  
329 Switzerland, and the United Kingdom). Tables showing investigational sites, principal  
330 investigators, and numbers enrolled at each site and in each country are included in the  
331 Appendix (pp.1-2). The study was completed on June 25, 2015, and a total of 413 men were  
332 enrolled: 206 randomised to the VTP group and 207 to the AS group. More subjects in the  
333 AS group (n=6) than in the VTP group (n=17) withdrew consent before study completion.  
334 Although unwillingness to accept randomisation to either group was an exclusion criterion,  
335 the sponsor anticipated that subjects randomised to AS might withdraw because they had  
336 entered the study to receive active treatment. The percentage of such withdrawals was less  
337 than expected. Otherwise, study completion and reasons for withdrawal were similar between  
338 the two groups (Figure 1).

339 Demographic and baseline disease characteristics were well balanced between the two groups  
340 and fit the profile of low-risk PC patients (Table 1). Of the 206 subjects randomised to VTP,  
341 nine did not subsequently start the VTP procedure: three who withdrew consent, three who  
342 were excluded because for exclusion criteria (bladder cancer discovered on pretreatment  
343 MRI, previous Gleason 3+4 biopsy, history of transurethral prostate resection), one who was  
344 discontinued by the investigator because of noncompliance, one who had a myocardial  
345 infarction, and one who was claustrophobic so unable to undergo the pretreatment MRI.

346 Of the 197 subjects who started the VTP procedure, one had an anaesthesia reaction before  
347 receipt of any padeliporfin or laser treatment. In all, 196 subjects received initial VTP (Figure  
348 1). Of these, 62 received subsequent contralateral treatment, 11 received retreatment, and two



349 received both contralateral treatment and retreatment. An LDI  $\geq 1$  was achieved in 252 (98%)  
350 of 254 initial treatments of a lobe. Prostate lobes that were retreated were less likely to  
351 achieve an LDI  $\geq 1$ , although they were exposed to the same energy of 200 J/cm (appendix  
352 p.2).

353 All 413 randomised subjects were included in the efficacy analysis (Figure 1). Padeliporfin  
354 VTP delayed progression from low-risk to moderate or higher-risk PC and reduced the  
355 probability of a positive biopsy results at Month 24 compared to AS (Table 2). Padeliporfin  
356 VTP doubled time to progression from 14.1 (95% CI: 12.9 to 23.8) months to 28.3 (95% CI:  
357 26.0 to 30.6) months ( $p < 0.0001$ ). The rate of progression over 24 months was reduced to  
358 approximately one-third that of AS (adjusted hazard ratio = 0.34; 95% CI: 0.24, 0.46;  
359  $p < 0.0001$ ). The distribution of predefined progression criteria showed that padeliporfin VTP  
360 was efficacious against the individual parameters of the composite progression endpoint. The  
361 principal determinants of progression were Gleason grade  $\geq 4$  and increases in number of  
362 positive cores and cancer core length, which all showed substantial reduction in the  
363 padeliporfin VTP group. The regression coefficients showed no effect of treatment group or  
364 baseline characteristics. Padeliporfin VTP also increased the probability of a negative Month  
365 24 biopsy by from 13.5% (28 of 207 subjects) to 49.0% (101 of 206 subjects) (adjusted risk  
366 ratio: 3.67; 95% CI: 2.53, 5.33);  $p < 0.0001$ ). Eight subjects experienced a severe PC-related  
367 event within 24 months, but only one of the subjects who did have such an event (both T3 PC  
368 and metastasis) was in the VTP group. This subject was probably under-staged at study entry.  
369 His first protocol-required biopsy resulted in a Gleason upgrading that, for the purposes of  
370 the study, constituted his first—and therefore reported—progression event. Subsequent  
371 investigation revealed a locally advanced PC, and metastasis was detected on further staging  
372 investigation. VTP exposure was associated with a reduction in the rate of radical therapy  
373 compared to men allocated to AS (12 [5.8%] of 206 subjects versus 60 [29.0%] of 207

374 subjects;  $p < 0.0001$ ) and in time to radical therapy ( $p < 0.0001$ ) (Figure 2). For subjects whose  
375 PC did not progress during the study, padeliporfin VTP also produced clinically and  
376 statistically significant decrease compared to AS at Month 24 in all mean tumour burden  
377 parameters: total number of positive cores (0.9 vs 2.3;  $p < 0.0001$ ), total cancer core length  
378 (2.6 vs 6.8 mm;  $p < 0.0001$ ), and maximum cancer core length (1.6 vs 3.4 mm;  $p < 0.0001$ ).  
379 Moreover, VTP produced a stable reduction in PSA of about 3 ng/mL over the course of the  
380 study.

381 The nine subjects randomised to VTP but who had no treatment-related procedure were  
382 excluded from the safety analysis (Figure 1). In the VTP group, IIEF-15 and IPSS  
383 assessments showed transient deterioration in erectile and urinary function, but the Month 24  
384 result was comparable between the two groups (appendix p.3). Month 24 IPSS was 6.6  
385 (standard deviation [SD]: 5.47) for VTP and 8.2 (SD: 6.47) for AS, and Month 24 IIEF-15  
386 was 15 (SD: 10.70) for VTP and 16.8 (SD: 11.17) for AS. These results show no significant  
387 effect of padeliporfin VTP on genitourinary function compared to AS. The mean EQ-5D  
388 questionnaire scores at Month 24 in both the VTP and AS groups were slightly decreased  
389 from baseline with no difference in the two groups (82.5 [SD: 12.31] in the VTP group and  
390 81.8 [SD: 12.09] in the AS group), indicating no decrease in quality of life associated with  
391 VTP at Month 24 (appendix p.2).

392 As expected, both the incidence and severity of AEs and SAEs were higher in the VTP group  
393 than in the AS group (Table 3). Most subjects in the VTP group experienced an AE, most of  
394 which were mild or moderate in severity and self-limited. The most commonly reported AEs  
395 in the padeliporfin VTP group were urinary tract infections (23 AEs in 21 [10.7%] subjects)  
396 and AEs in the renal and urinary disorders (280 AEs in 133 [67.5%] of 197 subjects) and  
397 reproductive system and breast disorders system organ classes (197 AEs in 121 [61.4%] of  
398 197 subjects), and these AEs accounted for the largest differences between the treatment

399 groups. AEs related to the study drug, device, or procedure were common but generally not  
400 severe. Most of these related AEs occurred during the procedure or in the days immediately  
401 after the procedure and resolved quickly without sequelae. The reporting of pain that was  
402 thought to be related to the procedure (due to the transcutaneous needle placement, due to the  
403 swelling of the prostate or both) was captured by the term ‘perineal pain’. This was reported  
404 by 30 (15%) men allocated to the VTP group and by 1(0.5%) man in the AS group.

405 Three subjects experienced events that were more long-lasting: two with urethral strictures  
406 requiring endoscopic dilation and one case of urinary incontinence in a subject who had  
407 previously undergone transurethral prostatectomy (TURP). Men with a history of surgery for  
408 benign prostatic hypertrophy (including TURP) were subsequently excluded from the study  
409 (via protocol amendment 23 October 2012) for safety reasons. All other reports of  
410 incontinence were self-limited, were usually urge-related and occurred in the period after  
411 catheter withdrawal. Incontinence management was at the discretion of the investigator. The  
412 most common related SAE in the VTP group was urinary retention. Typically this event  
413 occurred on the first attempt to withdraw the urinary catheter (day-1 post-op). This was  
414 managed with immediate recatheterization. The timing of a second attempt at removal of the  
415 urinary catheter was left to the discretion of the local investigator. All 15 retention cases  
416 resolved within two months. No subject discontinued VTP because of an AE. Three subjects  
417 discontinued the study because of AEs. One subject in the AS group developed ureteric  
418 cancer. One subject in the VTP group had an anaphylactic reaction to the anaesthesia  
419 administered at the start of the VTP procedure; he had received no padeliporfin or VTP. One  
420 subject in the VTP group died from a myocardial infarction during mountain climbing  
421 approximately eight months after padeliporfin VTP, and the investigator assessed the AE as  
422 unrelated to study drug, device, or procedure.

423 An independent Data and Safety Monitoring Board reviewed safety data approximately every  
424 3 months throughout the study and advised the study sponsor on matters of subject safety. At  
425 all meetings, the members unanimously agreed that no safety issues had emerged in the  
426 study.

427

## 428 **DISCUSSION**

429 VTP doubled time to progression (from 14.1 to 28.3 months), reduced the progression rate to  
430 approximately one-third that of AS, and increased the probability of a negative prostate  
431 biopsy at 24 months post-treatment from 13.5% to 49.0%. VTP was also safe and well  
432 tolerated with only minor and transient deterioration in genitourinary function. Our study has  
433 shown that partial-gland ablation by VTP influences the course of PC in the short-to-medium  
434 term. First, the proportion of men who transition from a cancer status to cancer-free status  
435 was increased. Second, the proportion of men who progress from a histologically defined  
436 low-risk status to a higher one is diminished. As a result, fewer men chose to undergo radical  
437 therapy during the study period. Moreover, these benefits were achieved safely, efficiently,  
438 and without compromising genitourinary function when assessed at 12 and 24 months after  
439 VTP.

440 Since this is the first comparative efficacy study of its type, it is important to consider the  
441 methodological considerations that were inherent in its design and conduct. The first relates  
442 to the population studied. By today's standards this population might be considered low risk.  
443 However, whilst the study was in development and being discussed with the EMA, neither  
444 AS nor focal therapy were accepted as standard care. The EMA agreed that we could  
445 reasonably exclude very-low-risk patients. Therefore, lower and upper thresholds of risk  
446 (defined by Gleason pattern and tumour burden) were set, below which and above which men

447 were excluded. This low-risk group was the only one that could have been studied at the time.  
448 Were the study designed today, given the changes to risk categorisation, it is likely that men  
449 with well characterised PC and low volume secondary Gleason pattern 4 would be included.<sup>16</sup>

450 A second limitation relates to rapidly changing practice in risk stratification of PC patients,  
451 most significantly the use of MRI in the diagnostic and the re-evaluation phases of both AS  
452 and focal therapy.<sup>17,18</sup> When the study began, few units offered MRI to patients on AS or as  
453 part of the work-up for focal therapy. Now it is difficult to imagine using either strategy  
454 without MRI. Although only men assigned to VTP had MRI in this study, images were used  
455 only for treatment planning, not for detection or staging. The only way in which unilateral  
456 use of MRI could have biased subjects' allocation was the detection of colorectal or bladder  
457 cancer, which would have triggered a study withdrawal. If the study were repeated today,  
458 MRI would play an important role in subject selection and risk stratification for both  
459 interventions.<sup>19</sup>

460 A third concern is discriminating true progression from reclassification. When using a  
461 biopsy-based strategy to refine the risk stratification at given intervals in AS, upgrading  
462 (transition from an exclusive Gleason pattern 3 status to one with elements of Gleason pattern  
463 4 or 5) occurs. Determining whether the observed increase in the Gleason pattern is a  
464 correction of inherent diagnostic imprecision or the product of true disease progression has  
465 proved challenging. Whilst no universal definition of clinical significance exists, recently  
466 published MRI studies have used the presence of Gleason pattern 4 as the minimum  
467 definition of clinically significant PC.<sup>17,18</sup> Physicians have recommended treatment upon  
468 upgrading irrespective of its underlying cause. This strategy appears prudent given that  
469 recently published data from two mature AS series have identified higher risk groups (within  
470 the risk profile suitable for AS) that are at greater risk of progression.<sup>2,20,21</sup>

471 The final issue relates to the efficacy endpoints evaluated. If endpoints such as progression to  
472 metastases or death had been used, the natural history of low-risk PC would have required a  
473 very large study conducted over two decades. Some experts advocate prioritizing of shorter-  
474 term, relevant outcomes that are important to patients to support patients and their physicians  
475 in their clinical decision-making.<sup>22</sup>

476 This multicentre study has demonstrated that padeliporfin VTP can be implemented widely  
477 and delivered effectively and safely. The latter issue deserves some qualification. Exposure to  
478 VTP resulted in an increase in the frequency of SAEs from 1 in 10 men on AS to 1 in 3 men  
479 who received VTP. Most of the events were expected, genitourinary in nature, and self-  
480 limited. The most important of these events was failure to void on catheter removal (urinary  
481 retention). The event was managed by replacement of the urethral catheter and extension of  
482 the period of dependent urinary drainage.

483 It is worth noting that most study sites had no prior experience in delivering focal therapy, let  
484 alone VTP. Study recruitment was timely over a large geographical area, a scenario that  
485 contrasts with the many previous attempts to undertake randomised, comparative studies of  
486 early PC treatment, which either failed to recruit completely or closed because of poor  
487 recruitment.<sup>23</sup> Feasibility is an important attribute for surgical interventions, and our results  
488 demonstrate that VTP can be taught, learned, and delivered by a range of health care  
489 providers and systems. This study was performed at a large number of centres and in a  
490 variety of healthcare systems, few of which had any previous experience with VTP, and yet  
491 we managed to achieve a very low rate of permanent urinary toxicity. Since our  
492 understanding and management of early PC have changed so much in the last few years, it is  
493 worth speculating on how padeliporfin VTP might be used with current diagnostics and risk  
494 stratification, which are unrecognizable from those at the time of study design. Adoption of  
495 MRI and targeted biopsy into the clinical pathway has created more precise risk stratification,

496 allowing a more nuanced approach to men with a new PC diagnosis. Given that MRI is now  
497 widely used within the diagnostic pathway but was not used for diagnosis or risk stratification  
498 in our study, it is worth speculating on how the diagnostic process may be influenced by the  
499 results of this study. First, it is likely that a pathway based on MRI—because of its role as a  
500 triage test between an elevated PSA and biopsy—will result in a reduction of the number of  
501 men biopsied and in the proportion of men receiving the diagnosis of clinically insignificant  
502 PC. In contrast, men with an MRI abnormality will undergo targeted biopsy (something that  
503 was not possible without MRI), resulting in a greater sensitivity for clinically significant  
504 disease. It is very likely that the men with clinically significant isolated lesions will be the  
505 candidates for focal prostate therapy. Men who do not need treatment should not have it. Men  
506 who require whole-gland treatment because of bilateral clinically significant disease should  
507 be offered it. Men with locally advanced disease should be offered multimodality therapy.  
508 However, men who have low-risk, localised disease can now choose, on the basis of the  
509 evidence that our study has generated, how to approach tissue preservation.

510 More research is needed to address unanswered questions, the principal one being the long-  
511 term effect of tissue-preserving treatment on PC control rates. One unknown element is the  
512 efficacy of padeliporfin VTP in eradicating cancers of different grades within the target  
513 volume. A study in men with Gleason pattern 4 (NCT01875393) has been submitted for  
514 publication. Another uncertainty relates to the stability of the tissue that lies beyond the  
515 treatment zone. This question requires long-term follow-up, which has been initiated in the  
516 men from Study CLIN1001 PCM301.

## 517 **CONTRIBUTORS**

518 The sponsor, STEBA Biotech S.A., developed the study design in consultation with the study  
519 investigators and the EMA. BA performed the statistical analysis and interpretation on behalf

520 of the sponsor. AAzzouzi, SV, EB, AC, FK, HVP, CGS, JR, GS, ES, AAAlcaraz, TTT, DJR,  
521 FGV, GA, ME, and the PCM301 Study Group conducted the study and collected the data.  
522 FMJD chaired the Data Safety Monitoring Board and GF and CG served on the Outcomes  
523 Review Panel. ME prepared the first draft of the manuscript and with Anne McDonough, a  
524 professional medical writer funded by the sponsor. All authors contributed to the final data  
525 interpretation and final draft of the report and approved submission for publication.

526



527 **DECLARATION OF INTEREST**

528 AAzzouzi, SV, EB, AC, FK, HGV, CGS, JR, GS, ES, AAlcaraz, TTT, DJR, FGV, GA, and  
529 ME received payment from STEBA as investigators on this study. AA and ME have also  
530 acted as consultants and proctors for STEBA. FMJD, GF, and CG received payment from  
531 STEBA for other roles on the study (Data Safety Monitoring Board, Outcomes Review  
532 Panel). BA is a statistical consultant to STEBA. FB and BG are employees of STEBA. FGV  
533 reports receipt of funding for research from Astellas Pharma and acting as a paid proctor for  
534 Intuitive Surgical, Inc. AAlcaraz reports payment for speaking engagements from several  
535 companies (Astellas Pharma, Janssen Pharmaceutica, Sanofi, Bayer, STEBA Biotech S.A.,  
536 Olympus Corporation). TTT reports being an advisor for Astellas Pharma, Ferring  
537 Pharmaceuticals, Orion Corporation, and Bayer and receiving institutional funding from  
538 Astellas Pharma, Ferring Pharmaceuticals, Medivation, Inc, Orion Corporation, and Bayer.  
539 ME reports acting as a principal/co-investigator in a number of PC studies supported by  
540 SonaCare Medical, Sophiris Bio Inc, and TROD Medical and as a consultant/advisor to GSK  
541 and Sanofi-Aventis, being a founding partner of London Urology Associates, and  
542 shareholdings in Nuada Medical Ltd.

543 **ACKNOWLEDGEMENTS**

544 We thank the patients who agreed to participate in this study.

545 We thank Drs. Peter Scardino and Michael Zelefsky (Memorial Sloane Kettering Cancer  
546 Center, New York, USA) for their very helpful comments and advice on earlier versions of  
547 this manuscript.

548 Dr. Emberton is a United Kingdom National Institute of Health Research (NIHR) Senior  
549 Investigator. His research is supported by the UCLH/UCL NIHR Biomedical Research  
550 Centre, London, UK.

## 551 REFERENCES

- 552 1. Mottet N, Bellmunt JE, van den Bergh RCN, et al. Guidelines on Prostate Cancer.  
553 European Association of Urology; 2015. [http://uroweb.org/wp-content/uploads/EAU-](http://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2015-v2.pdf)  
554 [Guidelines-Prostate-Cancer-2015-v2.pdf](http://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2015-v2.pdf). Accessed 9 June 2016.
- 555 2. Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active  
556 surveillance cohort of patients with prostate cancer. *J Clin Oncol*. 2015; **33**: 272–7.
- 557 3. Klotz L, Emberton M. Management of low risk prostate cancer: active surveillance  
558 and focal therapy. *Curr Opin Urol*. 2014; **24**: 270–9.
- 559 4. van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC..  
560 Novel tools to improve patient selection and monitoring on active surveillance for  
561 low-risk prostate cancer: a systematic review. *Eur Urol*. 2014; **65**: 1023–31.
- 562 5. Ahmed HU, Hindley RG, Dickinson L, et al. Focal therapy for localised unifocal and  
563 multifocal prostate cancer: a prospective development study. *Lancet Oncol*. 2012; **13**:  
564 622–32.
- 565 6. Valerio M, Ahmed HU, Emberton M, et al. The role of focal therapy in the  
566 management of localised prostate cancer: a systematic review. *Eur Urol*. 2014; **66**:  
567 732–51.
- 568 7. Azzouzi AR, Barret E, Bennet J, et al. TOOKAD® soluble focal therapy: pooled  
569 analysis of three phase II studies assessing the minimally invasive ablation of  
570 localized prostate cancer. *World J Urol*. 2015; **33**: 945–53.
- 571 8. Azzouzi AR, Barret E, Moore CM, et al. TOOKAD(®) Soluble vascular-targeted  
572 photodynamic (VTP) therapy: determination of optimal treatment conditions and

- 573 assessment of effects in patients with localised prostate cancer. *BJU Int.* 2013; **112**:  
574 766–74.
- 575 9. Welty CJ, Cowan JE, Nguyen H, et al. Extended followup and risk factors for disease  
576 reclassification in a large active surveillance cohort for localized prostate cancer. *J*  
577 *Urol.* 2015;**193**: 807-11.
- 578 10. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1:  
579 screening, diagnosis, and treatment of clinically localised disease. *Eur Urol.* 2011; **59**:  
580 61–71.
- 581 11. American Urological Association. Guideline for the Management of Clinically  
582 Localized Prostate Cancer: 2007 Update.  
583 <http://www.auanet.org/common/pdf/education/clinical-guidance/Prostate-Cancer.pdf>.  
584 Accessed 9 June 2016.
- 585 12. Moore CM, Azzouzi AR, Barret E, et al. Determination of optimal drug dose and light  
586 dose index to achieve minimally invasive focal ablation of localised prostate cancer  
587 using WST11-vascular-targeted photodynamic (VTP) therapy. *BJU Int.* 2015; **116**:  
588 888–96.
- 589 13. Azzouzi AR, Lebdaï S, Benzaghrou F, Stief C. Vascular-targeted photodynamic  
590 therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the  
591 procedure. *World J Urol.* 2015; **33**: 937–44.
- 592 14. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association  
593 symptom index for benign prostatic hyperplasia. The Measurement Committee of the  
594 American Urological Association. *J Urol.* 1992; **148**: 1549–57.
- 595 15. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The  
596 international index of erectile function (IIEF): a multidimensional scale for  
597 assessment of erectile dysfunction. *Urology* 1997; **49**: 822–30.

- 598 16. Epstein JI. A new contemporary prostate cancer grading system. *Ann Pathol.* 2015;  
599 **35**: 474–6.
- 600 17. Panebianco V, Barchetti F, Sciarra A, et al. Multiparametric magnetic resonance  
601 imaging vs. standard care in men being evaluated for prostate cancer: a randomized  
602 study. *Urol Oncol.* 2015; **33**: 17.e1–7.
- 603 18. Recabal P, Assel M, Sjoberg DD, et al. The efficacy of multiparametric magnetic  
604 resonance imaging and magnetic resonance imaging targeted biopsy in risk  
605 classification for patients with prostate cancer on active surveillance. *J Urol.* 2016;  
606 **196**: 374-81.
- 607 19. Jarow JP, Ahmed HU, Choyke PL, Taneja SS, Scardino PT. Partial gland ablation for  
608 prostate cancer: report of a Food and Drug Administration, American Urological  
609 Association, and Society of Urologic Oncology Public Workshop. *Urology* 2016; **88**:  
610 8–13.
- 611 20. Henderson DR, de Souza NM, Thomas K, et al. Nine-year follow-up for a study of  
612 diffusion-weighted magnetic resonance imaging in a prospective prostate cancer  
613 active surveillance cohort. *Eur Urol.* 2015; pii: S0302-2838(15)00980-X. doi:  
614 10.1016/j.eururo.2015.10.010. [Epub ahead of print].
- 615 21. Godtman RA, Holmberg E, Khatami A, Pihl CG, Stranne J, Hugosson J. Long-term  
616 results of active surveillance in the Göteborg randomized, population-based prostate  
617 cancer screening trial. *Eur Urol.* 2016; pii: S0302-2838(16)30026-4. doi:  
618 10.1016/j.eururo.2016.03.048. [Epub ahead of print].
- 619 22. D'Amico AV. Personalizing the use of active surveillance as an initial approach for  
620 men with newly diagnosed prostate cancer. *J Clin Oncol.* 2015; **33**: 3365–6.
- 621 23. Ahmed HU, Berge V, Bottomley D, et al. Can we deliver randomized trials of focal  
622 therapy in prostate cancer? *Nat Rev Clin Oncol.* 2014; **11**: 482–91.

624 Table 1. Demographic and baseline prostate cancer characteristics

Characteristic	Padeliporfin VTP N = 206	Active surveillance N = 207	Total N = 413
Age (years)			
Mean (SD)	64.2 (6.7)	62.9 (6.7)	63.5 (6.7)
Range: minimum, maximum	45, 85	44, 79	44, 85
Race			
Caucasian, n (%)	202 (98.1)	206 (99.5)	408 (98.8)
Other, n (%)	4 (2.9)	1 (0.5)	5 (1.2)
Body mass index (kg/m <sup>2</sup> )			
Mean (SD)	26.5 (3.3)	27.3 (4.0)	26.9 (3.7)
Range: minimum, maximum	18.8, 38.6	18.8, 44.8	18.8, 44.8
Time since diagnosis (months)			
Mean (SD)	6.3 (8.5)	6.0 (7.9)	6.2 (8.2)
Range: minimum, maximum	0.2, 54.2	0.2, 47.4	0.2, 54.2
TNM staging			
T1a, n (%)	1 (0.5)	0	1 (0.2)
T1c, n (%)	177 (85.9)	180 (87.0)	357 (86.4)
T2a, n (%)	28 (13.6)	27 (13.0)	55 (13.3)
PSA (ng/mL)			
Mean (SD)	6.2 (2.1)	5.9 (2.0)	6.1 (2.1)
Range: minimum, maximum	0.1, 10.0	0.5, 10.0	0.1, 10.0
Estimated prostate volume (cc)			
Mean (SD)	42.5 (12.5)	42.5 (11.8)	42.5 (12.1)
Unilateral disease, n (%)	157 (76.2)	163 (78.7)	320 (77.5)
Bilateral disease, n (%)	49 (23.8)	44 (21.3)	93 (22.5)
Total number of pretreatment biopsy cores			
Mean (SD)	13.6 (3.3)	13.6 (3.6)	13.6 (3.4)
Range: minimum, maximum	10, 25	10, 26	10, 26
Total number of pretreatment biopsy cores with cancer			
Mean (SD)	2.1 (0.7)	2.0 (0.7)	2.1 (0.7)
Range: minimum, maximum	1, 3	1, 3	1, 3
1 core, n (%)	39 (18.9)	52 (25.1)	91 (22.0)
2 cores, n (%)	110 (53.4)	100 (48.3)	210 (50.8)
3 cores, n (%)	57 (27.7)	55 (26.6)	112 (27.1)
Total cancer core length (mm)			
Mean (SD)	4.3 (2.3)	3.8 (2.4)	4.1 (2.4)
Range: minimum, maximum	0 <sup>a</sup> , 14	0 <sup>a</sup> , 11	0, 14

SD = standard deviation; TNM = tumour, nodes, metastasis; VTP = vascular-targeted photodynamic therapy.  
<sup>a</sup> Some of the subjects included on the basis of two biopsies at the beginning of the study had one of those two biopsies negative.

**Table 2. Co-primary efficacy endpoints**

Endpoint <sup>a</sup>	Padeliporfin VTP N = 206 n (%)	Active surveillance N = 207 n (%)	Padeliporfin VTP vs active surveillance	
			Ratio (95% CI)	p value
Progression	58 (28.2)	120 (58.0)	Adjusted <sup>b</sup> hazard ratio 0.34 (0.24, 0.46)	<0.001 <sup>c</sup>
Criteria for progression <sup>d</sup>				
More than three cores positive	23 (11.2)	58 (28.0)	NC	<0.001 <sup>e</sup>
Gleason ≥4	49 (23.8)	91 (44.0)	NC	<0.001 <sup>e</sup>
Cancer core length >5 mm	25 (12.1)	51 (24.6)	NC	0.001 <sup>e</sup>
PSA >10 ng/mL in three consecutive measures	3 (1.5)	14 (6.8)	NC	0.007 <sup>e</sup>
Any T3 prostate cancer	0	4 (1.9)	NC	NA
Metastasis	0	0	NC	NA
Prostate cancer-related death	0	0	NC	NA
Negative Biopsy at Month 24	101 (49.0)	28 (13.5)	Adjusted <sup>f</sup> risk ratio 3.67 (2.53, 5.33)	<0.001 <sup>e</sup>

CI = confidence interval; NA = not applicable; NC = not calculated; VTP = vascular-targeted photodynamic therapy.

<sup>a</sup> The Hochberg procedure was used to adjust for multiplicity of the two co-primary endpoints.

<sup>b</sup> Cox proportional-hazards model with treatment as fixed effect and baseline age, number of cores positive, prostate volume, and disease status (unilateral/bilateral) as covariates.

<sup>c</sup> From the log-rank test of equality of survival curves across treatment groups Cox proportional-hazards model with treatment as fixed effect and baseline age, number of cores positive, prostate volume, and disease status (unilateral/bilateral) as covariates.

<sup>d</sup> A subject might have met > 1 criterion for progression.

<sup>e</sup> From Pearson's chi-square test for observed success.

<sup>f</sup> Logistic regression model with treatment as fixed effect and baseline age, number of cores positive, prostate volume, and disease status (unilateral/bilateral) as covariates.

**Table 3. Adverse events**

AE category	Padeliporfin VTP N = 197*		Active surveillance N = 207	
	Subjects n (%)	Events n	Subjects n (%)	Events n
All AEs	187 (94.9)	939	114 (55.1)	307
Drug, device, or VTP procedure-related AE	155 (78.7)	551	NA	NA
All SAEs	60 (30.5)	88	21 (10.1)	25
Drug, device, or VTP procedure-related SAE	30 (15.2)	39	NA	NA
AE leading to study discontinuation	2 (1.0)	2	1 (0.5)	1
AE leading to death	1 (0.5)	1	0	0
<b>Adverse Events Occurring in ≥ 10% of Subjects in Either Group</b>				
<b>System Organ Class Preferred Term</b>	<b>Subjects n (%)</b>		<b>Subjects n (%)</b>	
<b>Infections and infestations</b>				
Urinary tract infection	21 (10.7)		9 (4.3)	
<b>Renal and urinary disorders</b>				
Dysuria	54 (27.4)		5 (2.4)	
Haematuria	56 (28.4)		6 (2.9)	
Micturition urgency	21 (10.7)		2 (1.0)	
Pollakiuria	20 (10.2)		6 (2.9)	
Urinary retention	32 (16.2)		2 (1.0)	
<b>Reproductive system and breast disorders</b>				
Erectile dysfunction	74 (37.6)		24 (11.6)	
Perineal pain	30 (15.2)		1 (0.5)	
<b>Adverse Events by Severity</b>				
<b>AE Grade System Organ Class Preferred Term</b>	<b>Subjects n (%)</b>		<b>Subjects n (%)</b>	
<b>Grade 1 (mild)</b>	<b>49 (24.9)</b>		<b>42 (20.3)</b>	
<b>Grade 2 (moderate)</b>	<b>94 (47.7)</b>		<b>52 (25.1)</b>	
<b>Grade 3 (severe)</b>	<b>40 (20.3)</b>		<b>19 (9.2)</b>	
<b>Blood and lymphatic disorders</b>				
Thrombocytopenia	1 (0.5)		0	
<b>Cardiac disorders</b>				
Atrial fibrillation	1 (0.5)		0	
Myocardial infarction	1 (0.5)		2 (1.0)	
<b>Endocrine disorders</b>				
Hypothyroidism	1 (0.5)		0	
<b>Gastrointestinal disorders</b>				
Abdominal pain	1 (0.5)		0	
Gastrointestinal haemorrhage	0		1 (0.5)	
Inguinal hernia	2 (1.0)		0	
Rectal haemorrhage	1 (0.5)		0	
<b>General disorders and administration site conditions</b>				
Device failure	1 (0.5)		0	
Pyrexia	0		1 (0.5)	
<b>Immune system disorders</b>				
Drug hypersensitivity	2 (1.0)		0	
<b>Infections and infestations</b>				
Epididymitis	1 (0.5)		0	
Orchitis	1 (0.5)		0	
Otitis externa	0		1 (0.5)	
Staphylococcal infection	0		1 (0.5)	
Urinary tract infection	2 (1.0)		2 (1.0)	
<b>Injury, poisoning and procedural complications</b>				
Accident	1 (0.5)		0	
Cranio-cerebral injury	1 (0.5)		0	
Procedural pain	0		1 (0.5)	
<b>Investigations</b>				
Fibrin D dimer increased	2 (1.0)		0	
<b>Musculoskeletal and connective tissue disorders</b>				
Arthralgia	1 (0.5)		0	
Osteoarthritis	0		1 (0.5)	
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>				
Ear neoplasm	0		1 (0.5)	
Neuroendocrine carcinoma	1 (0.5)		0	
Prostate cancer	1 (0.5)		0	
Tongue cancer recurrent	0		1 (0.5)	
Tonsillar neoplasm	1 (0.5)		0	
Ureteric cancer metastatic	0		1 (0.5)	

Ureteric cancer regional	0	1 (0.5)
<b>Nervous system disorders</b>		
Cerebrovascular accident	1 (0.5)	0
Headache	1 (0.5)	0
Transient ischaemic attack	0	1 (0.5)
<b>Psychiatric disorders</b>		
Depression	1 (0.5)	1 (0.5)
<b>Renal and urinary disorders</b>		
Dysuria	3 (1.5)	0
Haematuria	1 (0.5)	0
Urinary incontinence	2 (1.0)	1 (0.5)
Urinary retention	3 (1.5)	1 (0.5)
<b>Reproductive system and breast disorders</b>		
Ejaculation failure	2 (1.0)	0
Erectile dysfunction	2 (1.0)	3 (1.4)
Perineal pain	1 (0.5)	0
Prostatic pain	1 (0.5)	0
Prostatitis	3 (1.5)	1 (0.5)
<b>Skin and cutaneous tissue disorders</b>		
Purpura	1 (0.5)	0
<b>Surgical and medical procedures</b>		
Aortic valve replacement	0	1 (0.5)
Cataract operation	1 (0.5)	0
Facial operation	1 (0.5)	0
Knee arthroplasty	1 (0.5)	0
<b>Vascular disorders</b>		
Phlebitis	0	1 (0.5)
Thrombosis	0	1 (0.5)
<b>Grade 4 (life-threatening)</b>	<b>3 (1.5)</b>	<b>1 (0.5)</b>
<b>Cardiac disorders</b>		
Angina unstable	1 (0.5)	0
Myocardial infarction	0	1 (0.5)
<b>Immune system disorders</b>		
Anaphylactic reaction	1 (0.5)	0
<b>Respiratory, thoracic and mediastinal disorders</b>		
Bronchospasm	1 (0.5)	0
<b>Grade 5 (death)</b>	<b>1 (0.5)</b>	<b>0</b>
<b>Cardiac disorders</b>		
Myocardial infarction	1 (0.5)	0
AE = adverse event; SAE = serious adverse event; VTP = vascular-targeted photodynamic therapy.		
* The nine subjects randomised to VTP but who had no treatment-related procedure were excluded from analysis of safety.		



## **FIGURE LEGENDS (IN-TEXT)**

**Figure 1. Disposition of subjects by treatment group**

**Figure 2. Time to initiation of radical therapy by treatment group – Kaplan-Meier analysis**